对“外周NLRP3炎症小体激活与阻塞性睡眠呼吸暂停患者现患及新发慢性肾脏病的关联：一项前瞻性研究”的评论

文献信息

中文摘要

本通信对Cai等人研究循环NLRP3与阻塞性睡眠呼吸暂停（OSA）患者现患及新发慢性肾脏病（CKD）的研究进行评论。纳入648名参与者、互补的横断面与前瞻性分析，以及对估算肾小球滤过率（eGFR）和蛋白尿的评估是重要优势。然而，若干方法学考量影响解读。现患CKD似乎使用基线eGFR或尿白蛋白-肌酐比值进行分类，而未一致确认慢性性。单次基线NLRP3测量可能不能反映长期生物学活性，而校正关联并不能确立超越既有危险因素的预测改善。OSA严重程度、夜间低氧血症和炎症标志物的可能因果作用也值得明确考虑。基于这些发现，未来多中心研究应通过重复肾脏测量确认CKD，评估NLRP3的系列可重复性，预先指定因果信息模型，并使用判别、校准、验证和决策曲线分析比较含与不含NLRP3的临床预测模型。这些步骤将有助于确定循环NLRP3是否为OSA中的肾脏风险分层提供有意义的增量价值。

英文摘要

This correspondence comments on the study by Cai et al. examining circulating NLRP3 and prevalent and incident chronic kidney disease (CKD) in patients with obstructive sleep apnea (OSA). The inclusion of 648 participants, complementary cross-sectional and prospective analyses, and evaluation of estimated glomerular filtration rate (eGFR) and albuminuria are important strengths. Nevertheless, several methodological considerations affect interpretation. Prevalent CKD appears to have been classified using baseline eGFR or urinary albumin-to-creatinine ratio without consistent confirmation of chronicity. A single baseline NLRP3 measurement may not reflect long-term biological activity, while adjusted associations do not establish improved prediction beyond established risk factors. The possible causal roles of OSA severity, nocturnal hypoxemia, and inflammatory markers also merit explicit consideration. Building on these findings, future multicenter studies should confirm CKD with repeat renal measurements, assess serial NLRP3 reproducibility, prespecify causally informed models, and compare clinical prediction models with and without NLRP3 using discrimination, calibration, validation, and decision-curve analysis. These steps would help determine whether circulating NLRP3 offers meaningful incremental value for renal risk stratification in OSA.